Statistics for Theravance Biopharma (id:6504 TBPH)

Valuation metrics

Market cap

472.56M

Enterprise value

438.33M

Trailing P/E (ttm)

-9.47

Forward P/E

160.17

PEG ratio

160.17

Price/Sales (ttm)

7.48

Price/Book (mrq)

2.54

Enterprise Value/Revenue

6.94

Enterprise Value/EBITDA

-11.46

Overview

Shares outstanding

49.17M

Float

21.22M

Shares short

4.92M

% Held by insiders

0.06%

% Held by institutions

0.97%

Average volume (10 days)

247.43K

Average volume (90 days)

Price summary

52-Week low

7.44

52-Week high

11.71

52-Week change

-10.56%

Beta

0.25

50-Day moving average

8.52

200-Day moving average

8.81

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-78.18%

Operating margin

-54.99%

Operational effectiveness

Return on assets

-6.41%

Return on equity

-22.88%

Income statement

Revenue (ttm)

1.29

Revenue per share (ttm)

1.29

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-38,236,000.00

Net income to common (ttm)

-49,401,000.00

Diluted EPS (ttm)

-1.03

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

91.36M

Total cash per share (mrq)

1.86

Total debt (mrq)

40.78M

Total Debt/Equity (mrq)

21.97

Current ratio (mrq)

497.00%

Book value per share (mrq)

3.79

Cash flow

Cash flow statement

-16,807,000.00

Levered free cash flow (LFCF)

-253,260,000.00